WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center Inc., a Delaware corporation (“AbbVie”), for $1.0 million..

马萨诸塞州沃尔瑟姆，2025年2月27日（GLOBE NEWSWIRE）——Mustang Bio, Inc.（“Mustang”或“公司”）（纳斯达克股票代码：MBIO），一家专注于将当今细胞疗法的医学突破转化为潜在治愈难治性癌症的临床阶段生物制药公司，今日宣布退出其位于马萨诸塞州伍斯特的制造工厂租赁，并同时以100万美元的价格向特拉华州公司AbbVie Bioresearch Center Inc.（“AbbVie”）剥离某些固定资产，包括家具和设备。

Mustang has relocated its corporate headquarters to 95 Sawyer Road, Waltham, Massachusetts.

Mustang已将其公司总部迁至马萨诸塞州沃尔瑟姆市索耶路95号。

Mustang expects to continue to rely on its academic partners and future contract manufacturing relationships to support clinical trials. As a result of the termination of its lease, the Company expects savings of approximately $2.0 million of cash expenses related to the lease over the next 24 months..

Mustang预计将继续依靠其学术合作伙伴和未来的合同制造关系来支持临床试验。由于租赁终止，公司预计在未来24个月内节省大约200万美元与租赁相关的现金支出。

The Company remains focused on advancing its existing portfolio and anticipates supporting and initiating a novel clinical trial with MB-109, a combination therapy of MB-108 (HSV-1 oncolytic virus) and MB-101 (IL13Rα2‐targeted CAR-T cell therapy) for the treatment of recurrent glioblastoma (“GBM”) and high-grade astrocytomas in the second half of 2025..

公司仍专注于推进其现有产品组合，并预计在2025年下半年支持和启动一项新的临床试验，使用MB-109（MB-108（HSV-1溶瘤病毒）和MB-101（靶向IL13Rα2的CAR-T细胞疗法）的联合疗法），用于治疗复发性胶质母细胞瘤（“GBM”）和高级别星形细胞瘤。

About MB-109 (MB-101 (IL13Rα2

关于MB-109（MB-101（IL13Rα2））

targeted CAR-T cells) + MB-108 oncolytic virus)

靶向CAR-T细胞）+ MB-108溶瘤病毒）

MB-109 is Mustang’s designation for the treatment regimen combining MB-101 (IL13Rα2‐targeted CAR-T cell therapy licensed from City of Hope) with MB-108 (HSV-1 oncolytic virus licensed from Nationwide Children’s Hospital). The combination is designed to leverage MB-108 to make immunologically “cold” tumors “hot” and potentially improve the efficacy of MB-101 CAR-T cell therapy.

MB-109是Mustang公司对结合MB-101（从希望之城授权的IL13Rα2靶向CAR-T细胞疗法）与MB-108（从全国儿童医院授权的HSV-1溶瘤病毒）的治疗方案的命名。该组合旨在利用MB-108将免疫学上的“冷”肿瘤转化为“热”肿瘤，并可能提高MB-101 CAR-T细胞疗法的疗效。

MB-108 oncolytic virus is first injected to infect tumor cells which, in turn, leads to reshaping of the tumor microenvironment (“TME”) through recruitment of endogenous CD8- and CD3-positive effector T-cells. This inflamed TME potentially permits MB-101 CAR-T cells injected into and around the tumor to better infiltrate into and throughout the tumor mass, undergo activation and, ideally, effect tumor cell killing..

MB-108溶瘤病毒首先被注射以感染肿瘤细胞，这反过来通过招募内源性CD8阳性和CD3阳性效应T细胞来重塑肿瘤微环境（“TME”）。这种炎症性的TME可能允许注入和围绕肿瘤的MB-101 CAR-T细胞更好地渗透到肿瘤组织中并扩散至整个肿瘤块，进而被激活，并理想地实现对肿瘤细胞的杀伤作用。

About Mustang Bio

关于野马生物

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market.

Mustang Bio, Inc. 是一家处于临床阶段的生物制药公司，专注于将当今细胞疗法领域的医学突破转化为治疗难治性癌症的潜在疗法。Mustang 旨在通过许可或获取所有权权益的方式获得这些技术的权利，为研发提供资金，并将技术进行转许可或推向市场。

Mustang has partnered with top medical institutions to advance the development of CAR-T therapies. Mustang’s common stock is registered under the Securities Exchange Act of 1934, as amended, and Mustang files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc.

Mustang 已与顶级医疗机构合作，以推进 CAR-T 疗法的开发。Mustang 的普通股已根据修订后的《1934 年证券交易法》注册，并且 Mustang 会定期向美国证券交易委员会（“SEC”）提交报告。Mustang 由 Fortress Biotech, Inc. 创立。

(Nasdaq: FBIO). For more information, visit .

（纳斯达克：FBIO）。欲了解更多信息，请访问 。

www.mustangbio.com

www.mustangbio.com

.

。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions.

本新闻稿包含根据修订后的《1933年证券法》第27A条和《1934年证券交易法》第21E条所定义的“前瞻性陈述”。这些陈述通常通过诸如“预期”、“相信”、“可能”、“估计”、“预计”、“目标”、“打算”、“期待”、“或许”、“计划”、“潜在”、“预测”、“预计”、“应该”、“将”、“会”以及类似表达来表示。

The Company’s forward-looking statements, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to make regulatory filings such as INDs and other applications and to obtain regulatory approvals for our product candidates, statements concerning the potential of therapies and product candidates and any other statements that are not historical facts.

公司的前瞻性声明包括但不限于与我们的增长战略和产品开发计划相关的任何声明，包括提交监管文件（如IND和其他申请）的时机以及我们获得产品候选物监管批准的能力，关于疗法和产品候选物潜力的声明，以及任何其他非历史事实的声明。

Actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties. Risks and uncertainties include, among other things, our need for substantial additional funds in the immediate future; risks that any actual or potential clinical trials may not initiate or complete in sufficient timeframes to advance the Company’s corporate objectives, or at all, or that any promising early results obtained therefrom may not be replicable; risks related to the satisfaction of the conditions necessary to transfer the lease of the Company’s manufacturing facility; disruption from the sale of the Company’s manufacturing facility making it more difficult to maintain business and operational relationships; negative effects of Company announcements on the market price of the Company’s common stock; the development stage of the Company’s primary .

由于诸多风险和不确定性，实际事件或结果可能与本新闻稿中描述的内容存在重大差异。风险和不确定性包括但不限于：公司近期对大量额外资金的需求；任何实际或潜在的临床试验可能无法在足够的时间内启动或完成，甚至完全无法推进公司企业目标，或任何早期有希望的结果可能无法复制；与满足公司生产设施租赁转让条件相关的风险；出售公司生产设施可能导致业务和运营关系更难以维系；公司公告对普通股市场价格的负面影响；公司主要产品处于开发阶段等。

Company Contacts:

公司联系人：

Jaclyn Jaffe and Nicole McCloskey

杰奎琳·贾菲和妮科尔·麦克洛斯基

Mustang Bio, Inc.

必治妥生物公司

(781) 652-4500

(781) 652-4500

ir@mustangbio.com

ir@mustangbio.com

Released February 27, 2025 • 4:05 PM EST

发布于2025年2月27日 • 美东时间下午4:05